40yrs
in pharmaceutical and biotech manufacturing
Pharma capital projects
We place qualified specialist suppliers into GMP facility programmes — before procurement opens.
The supplier shortlist for a new drug substance or fill-finish facility is settled twelve to twenty-four months before tender. We work inside that window, on both sides of it.
A typical GMP capital programmeWhere we work
- Programme announced
- Design & early engineering — shortlist set12–24 months before tender. Where we work.
- Tender opens — the list is already set
- Award
Track record across the team
The experience our partners bring from inside the programmes we place into.
18yrs
at Amgen across engineering, quality and site leadership
2
commercial biologics, Nplate and Prolia, taken from concept to commissioning
1
new fill-finish facility taken from commissioning through licensure in Juncos, Puerto Rico
The window
The decision is made long before the market is allowed to compete.
12–24months
Ahead of tender
Vendor qualification for a GMP programme is set during design and early engineering. By the time a package goes out, the people running the build already know who they want.
12–18months
To become qualified
A supplier who first appears at tender stage was never eligible. The advert is close to a formality — the room where the shortlist was built has already closed.
1bid at a time
How good firms lose
Specialist contractors find work after procurement opens, against everyone, on price. Visibility twelve months out is the difference between growing and bidding.
How we work
We don't send bids. We place partners.
Placement means qualification, and qualification is a proper process — one that starts with the programme, not the supplier.
Programme intelligence
We follow pharma, CDMO and biologics capital programmes from announcement through design, and speak peer-to-peer with the engineering and site leaders mapping their supplier requirements.
Capability mapping
Under NDA, we map a supplier's real scope against what programmes are actually specifying, and say plainly where it fits and where it doesn't.
Placement
We position qualified partners against live demand at formation, when the question programme owners are asking is who can actually deliver this? Suppliers get pipeline they can plan against. Programmes get delivery certainty.
A company that can't see work coming can't hire ahead of it. We give suppliers the one thing a bid never does — time.
Who we work with
Two sides of the same programme.
Programmes
Capital projects in pharmaceutical and biologics manufacturing
- Drug substance facilities Cell culture · fermentation
- Fill-finish and aseptic operations Class 100 · RABS · isolators
- Lyophilisation suites Cycle development · qualification
- CDMO and biosimilar site expansions Greenfield · brownfield
- Clinical to commercial transitions PAI readiness
Specialist suppliers
Engineering, construction and equipment firms of 50 to 1,000 people
- Cleanroom and modular cleanroom Design · build
- Process piping and hygienic systems Orbital · CIP/SIP
- Isolators, RABS and filling lines Aseptic
- HVAC, controls and automation GMP utilities
- Commissioning and qualification C&Q · CQV
- Bioprocess equipment Skids · vessels · single-use
Programmes inUnited StatesUnited KingdomIrelandSwitzerlandDenmark
The partners
A firm built around forty years inside the plant.
Sector experience from the top of GMP manufacturing — the calibre of operator a programme builds around — with a commercial engine that puts it in front of the right people.
Lanre Gbadamosi
Founder & CEO
London
Lanre runs the firm — programme intelligence, supplier engagement and the commercial side of every placement. His background is in delivery: leading programmes across government, banking and life-sciences procurement, including HM Revenue & Customs, NatWest Group and IQVIA, most recently with Capgemini Invent.
He founded Arvid Partners to bring a disciplined, delivery-led approach to a market that still runs on who you know — and to put Greg's experience in front of the programmes and suppliers who need it.
Greg Corcoran
Managing Director
Longmont, Colorado
Greg spent eighteen years inside Amgen's manufacturing network, moving between engineering, quality and site leadership as the company built out commercial biologics capacity. He led process equipment design for Nplate and Prolia from concept through commissioning, ran Quality Assurance for the new fill-finish facility in Juncos, Puerto Rico from commissioning to licensure, and closed his Amgen career as Engineering Director for the global fill/finish and lyophilisation network.
He later served as General Manager and Site Head at Rezolute, and has advised biopharma manufacturers on facility readiness, aseptic operations and regulatory inspection since 2015. He is a chemical engineer by training (Georgia Tech) with a Master of Management from Kellogg.
How engagements are structured
Retained, qualification-led, and aligned to the award.
Retained
An engagement fee and a monthly retainer. We take on a small number of suppliers per category so that placement stays credible with the programmes we speak to.
Qualification-led
Capability mapping comes first, under NDA. If a scope doesn't fit what programmes are specifying, we say so before either side spends money.
Minimum term
Six months. Vendor qualification runs on the programme's clock, not ours, and anything shorter sets a supplier up to quit before it works.
Success-aligned
A share of awarded work. Our return depends on placements that turn into contracts, which keeps us honest about who we put forward.
Make contact
If you're mapping supplier requirements for a programme, or you're a specialist supplier taking on new programme work — talk to us.
Discreet conversations. We'd rather place a partner where it's needed than push one at you.
United KingdomLondon
United StatesLongmont, Colorado